Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson innovative Medicine segment income before tax ($M) ($M)
Form 10-Q / 10-K Segment Note
Latest, Q3 2026
5,066
Period ended Sep 30, 2026
Change on a year earlier
-21.4%
6,446 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
31
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Innovative Medicine segment income before tax ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 5,066 | -21.4% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2026 | Jun 28, 2026 | 6,249 | +12.6% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2026 | Mar 29, 2026 | 5,317 | +2.1% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2025 | Dec 28, 2025 | 5,058 | +26.2% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2025 | Sep 28, 2025 | 6,446 | +43.8% | Form 10-Q (filed 2026-10-21) ↗ |
| Q2 2025 | Jun 29, 2025 | 5,552 | +1.7% | Form 10-Q (filed 2026-07-23) ↗ |
| Q1 2025 | Mar 30, 2025 | 5,210 | +4.9% | Form 10-Q (filed 2026-04-22) ↗ |
| Q4 2024 | Dec 29, 2024 | 4,009 | -5.4% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2024 | Sep 29, 2024 | 4,482 | -6.5% | Form 10-Q (filed 2025-10-22) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,459 | +13.4% | Form 10-Q (filed 2025-07-24) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,969 | +12.9% | Form 10-Q (filed 2025-04-23) ↗ |
| Q4 2023 | Dec 31, 2023 | 4,238 | +31.5% | Form 10-K (filed 2026-02-11) ↗ |
| Q3 2023 | Oct 1, 2023 | 4,794 | +14.5% | Form 10-Q (filed 2024-10-23) ↗ |
| Q2 2023 | Jul 2, 2023 | 4,812 | +8.9% | Form 10-Q (filed 2024-07-25) ↗ |
| Q1 2023 | Apr 2, 2023 | 4,402 | +12.2% | Form 10-Q (filed 2024-05-01) ↗ |
| Q4 2022 | Jan 1, 2023 | 3,223 | -21.1% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2022 | Oct 2, 2022 | 4,186 | -0.3% | Form 10-Q (filed 2023-10-27) ↗ |
| Q2 2022 | Jul 3, 2022 | 4,420 | +2.9% | Form 10-Q (filed 2023-07-31) ↗ |
| Q1 2022 | Apr 3, 2022 | 3,924 | -24.1% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Jan 2, 2022 | 4,087 | +18.0% | Form 10-K (filed 2024-02-16) ↗ |
| Q3 2021 | Oct 3, 2021 | 4,200 | +22.1% | Form 10-Q (filed 2022-10-27) ↗ |
| Q2 2021 | Jul 4, 2021 | 4,294 | -4.9% | Form 10-Q (filed 2022-07-29) ↗ |
| Q1 2021 | Apr 4, 2021 | 5,169 | +34.8% | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Jan 3, 2021 | 3,463 | +14.3% | Form 10-K (filed 2023-02-16) ↗ |
| Q3 2020 | Sep 27, 2020 | 3,439 | -1,649.1% | Form 10-Q (filed 2021-10-29) ↗ |
| Q2 2020 | Jun 28, 2020 | 4,514 | +22.8% | Form 10-Q (filed 2021-07-29) ↗ |
| Q1 2020 | Mar 29, 2020 | 3,834 | +64.5% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2019 | Dec 29, 2019 | 3,030 | +27.6% | Form 10-K (filed 2022-02-17) ↗ |
| Q3 2019 | Sep 29, 2019 | -222 | -107.7% | Form 10-Q (filed 2020-10-23) ↗ |
| Q2 2019 | Jun 30, 2019 | 3,677 | +0.7% | Form 10-Q (filed 2020-07-24) ↗ |
| Q1 2019 | Mar 31, 2019 | 2,331 | -36.4% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 30, 2018 | 2,375 | +106.7% | Form 10-K (filed 2021-02-22) ↗ |
| Q3 2018 | Sep 30, 2018 | 2,876 | +0.7% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2018 | Jul 1, 2018 | 3,651 | +6.9% | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2018 | Apr 1, 2018 | 3,666 | +0.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 1,149 | – | Form 10-K (filed 2019-02-20) ↗ |
| Q3 2017 | Oct 1, 2017 | 2,857 | – | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jul 2, 2017 | 3,414 | – | Form 10-Q (filed 2018-08-02) ↗ |
| Q1 2017 | Apr 2, 2017 | 3,663 | – | Form 10-Q (filed 2018-05-01) ↗ |
Breakdown
What makes up innovative medicine segment income before tax ($m)
- Innovative Medicine — Cost of products sold ($M)4,486 · Q3 2026
- Innovative Medicine — Selling, marketing and administrative expenses ($M)3,035 · Q3 2026
- Innovative Medicine — Research and development expense ($M)3,888 · Q3 2026
- Innovative Medicine — Other segment expense/(income), net ($M)282 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Innovative Medicine segment income before tax ($M) ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/seg_pti_im
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.